Oculis (NASDAQ:OCS) Sets New 52-Week Low - Should You Sell?

Key Points

• Oculis shares fell to a new 52-week low of $10.50, last trading at $10.56 versus a prior close of $11.31. The stock is well below its 50-day and 200-day moving averages of $12.38 and $19.62, respectively.
• Analyst sentiment remains generally positive despite recent target cuts: nine analysts rate Oculis a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and a $38 average price target.
• The clinical-stage biotech reported a quarterly loss of $0.20 per share on just $0.38 million in revenue, with analysts expecting a full-year loss of $2.01 per share. Oculis has strong liquidity, including a quick ratio of 8.35 and debt-to-equity ratio of 0.01, but continues to post negative profitability metrics.

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) reached a new 52-week low on Saturday . The company traded as low as $10.50 and last traded at $10.56, with a volume of 226612 shares trading hands. The stock had previously closed at $11.31.

Analyst Ratings Changes

A number of brokerages recently issued reports on OCS. Robert W. Baird cut their price objective on Oculis from $49.00 to $38.00 and set an "outperform" rating for the company in a research note on Monday, June 1st. JPMorgan Chase & Co. decreased their target price on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a report on Friday, July 17th. Needham & Company LLC dropped their price target on shares of Oculis from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Monday, June 1st. Finally, HC Wainwright reissued a "buy" rating on shares of Oculis in a research note on Tuesday, August 25th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Oculis Stock Performance

The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $12.38 and a two-hundred day moving average price of $19.62. The stock has a market cap of $612.27 million, a P/E ratio of -6.07 and a beta of 0.52.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The business had revenue of $0.38 million during the quarter. On average, sell-side analysts forecast that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after acquiring an additional 6,384 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Oculis during the 2nd quarter valued at approximately $393,000. Bank of America Corp DE grew its holdings in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company's stock valued at $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in Oculis in the fourth quarter worth $1,972,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.